In contrast to MS, the levels of SARS-CoV-2 induced IFN-γ release were lower in MG patients compared with controls (median SARS-CoV-2 IFN-γ 250.5 vs. controls 1545 mIU/mL, p < 0.04) (Figure 3). This evidence concerns the gene IFNG and myeloid sarcoma.